Clinical trials: Livedo Vasculitis
Systemic Sclerosis, Fatigue
Apollo Device for Fatigue in Systemic Sclerosis
The purpose of this study is to learn about the effect of Apollo (a vibrating wearable about the side of an Apple Watch) on fatigue, Raynaud symptoms, depression, quality of life, and disease symptoms in patients with systemic…
- Conditions
- Systemic Sclerosis, Fatigue, Raynaud Phenomenon
- Trial name
- NCT04854850
- Testing
- Apollo
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Raynaud Disease, Raynaud Phenomenon
Phototherapy For Treatment Of Raynaud's Phenomenon
To determine if blue light therapy can improve the symptoms of Raynaud's phenomenon, and provide parameters for ultimately designing commercial treatment devices, an investigational stationary phototherapy unit was designed and…
- Conditions
- Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome
- Trial name
- NCT04898036
- Testing
- Blue Light Therapy
- Where
- United States
- Sponsor
- University of Minnesota
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Systemic Sclerosis, Raynaud's Phenomenon
The Effects of Exercise in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is a multisystem connective tissue disease characterised by vascular abnormalities and fibrosis, including those of the skin and can be categorised as either Limited cutaneous scleroderma or Diffuse…
- Conditions
- Systemic Sclerosis, Raynaud's Phenomenon, Quality of Life
- Trial name
- NCT03058887
- Testing
- Exercise intervention - Cycling, Exercise intervention - arm cranking
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Sheffield Hallam University
Raynaud's Phenomenon, Systemic Sclerosis
The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic Sclerosis
The effect of deep oscillation and biofeedback on Raynaud's phenomenon secondary to systemic sclerosis (SSc) remains to be determined.
- Trial name
- NCT00946738
- Testing
- Biofeedback, Deep oscillation
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Charite University, Berlin, Germany
Raynaud's Disease, Raynaud Phenomena
Open Label Treprostinil Raynaud's Study
Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed.
- Conditions
- Raynaud's Disease, Raynaud Phenomena, Raynauds
- Trial name
- NCT07112183
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Raynaud
Tadalafil for the Treatment of Raynaud's
The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.
- Trial name
- NCT00822354
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
CREST Syndrome, Peripheral Vascular Disease
Exparel as a Nerve Block for Severe Hand Pain
The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.
- Conditions
- CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
- Trial name
- NCT02374320
- Testing
- liposomal bupivacaine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jose Soberon, MD
Cutaneous Manifestations, Skin Manifestations
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019.
- Conditions
- Cutaneous Manifestations, Skin Manifestations, COVID-19, COVID-19 Pneumonia
- Trial name
- NCT05094687
- Where
- Pakistan
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre
Systemic Sclerosis, Raynaud Disease
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
- Trial name
- NCT00004786
- Testing
- iloprost
- Volunteers
- 200 people
- Sponsor
- National Center for Research Resources (NCRR)
Raynaud Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phenomenon attacks in subjects with symptomatic Raynaud's Phenomenon…
- Trial name
- NCT03867097
- Testing
- Iloprost Injection, for intravenous use
- Where
- 16 sites in United States
- Volunteers
- 34 people
- Sponsor
- Civi Biopharma, Inc.
Raynaud Phenomenon
Tadalafil-Delivra and Raynaud's Phenomenon
A 4-8 week observational feasibility study of the use of the use of Tadalafil-Delivra in the treatment of Reynaud's Phenomena (RP).
- Trial name
- NCT03393325
- Testing
- Observation of treatment with Tadalafil-Delivra
- Where
- 2 sites in Canada
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Raynaud Phenomenon, Primary Raynaud Phenomenon
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of…
- Conditions
- Raynaud Phenomenon, Primary Raynaud Phenomenon, Raynaud Disease, Raynaud Syndrome
- Trial name
- NCT03869008
- Testing
- gammaCore Sapphire
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually…
- Trial name
- RE-WARM (NCT07748000)
- Testing
- LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm
- Volunteers
- 75 people
- Sponsor
- Liquidia Technologies, Inc.
Systemic Sclerosis (SSc)
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial.
- Trial name
- ASScERT-QoL (NCT06675344)
- Testing
- Apollo Neuro Device
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR
Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Vasospasm is a transient contraction causing a decrease in caliber of a vessel and thus a decrease in vascularization in a vascular territory leading to suffering of tissue in the sector concerned.
- Conditions
- Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR, Study of Patients and Their Relatives (With or Without Primary PR)
- Trial name
- RAY-GENE (NCT02202291)
- Testing
- Demonstration of genetic mutations causing Raynaud's phenomenon
- Where
- 6 sites in France
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Raynaud Phenomenon
Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon
The investigators aim at comparing the efficacy of a 2 weeks supplementation by L-citrulline or beetroot juice to L-citrulline placebo or denitrated beetroot juice respectively on Raynaud's phenomenon severity.
- Trial name
- NivOSe (NCT03749577)
- Testing
- L-citrulline, Beetroot juice, Denitrated beetroot juice
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02228850
- Testing
- Alprostadil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Scleroderma, Systemic, Scleroderma, Diffuse
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Early phases of systemic sclerosis is characterized by inflammatory and microvasculature alterations. Sildenafil citrate has been shown to have vasodilatory effects and to enhance vasculogenesis.
- Conditions
- Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Raynaud Phenomenon
- Trial name
- NCT01347008
- Testing
- Sildenafil citrate
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- Federal University of São Paulo